JP2009539848A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539848A5 JP2009539848A5 JP2009514375A JP2009514375A JP2009539848A5 JP 2009539848 A5 JP2009539848 A5 JP 2009539848A5 JP 2009514375 A JP2009514375 A JP 2009514375A JP 2009514375 A JP2009514375 A JP 2009514375A JP 2009539848 A5 JP2009539848 A5 JP 2009539848A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- alkyl
- membered
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 20
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 18
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 15
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- 150000001602 bicycloalkyls Chemical group 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- -1 2-((pyridin-3-yloxy) methyl) piperazine-1- yl Chemical group 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81127506P | 2006-06-06 | 2006-06-06 | |
| US60/811,275 | 2006-06-06 | ||
| US85283606P | 2006-10-19 | 2006-10-19 | |
| US60/852,836 | 2006-10-19 | ||
| US90124007P | 2007-02-13 | 2007-02-13 | |
| US60/901,240 | 2007-02-13 | ||
| PCT/US2007/013425 WO2007146066A2 (en) | 2006-06-06 | 2007-06-06 | Novel piperazines, pharmaceutical compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013125127A Division JP2013199489A (ja) | 2006-06-06 | 2013-06-14 | 新規ピペラジン、医薬組成物、およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009539848A JP2009539848A (ja) | 2009-11-19 |
| JP2009539848A5 true JP2009539848A5 (enExample) | 2010-07-22 |
| JP5363315B2 JP5363315B2 (ja) | 2013-12-11 |
Family
ID=38658579
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009514375A Expired - Fee Related JP5363315B2 (ja) | 2006-06-06 | 2007-06-06 | 新規ピペラジン、医薬組成物、およびその使用方法 |
| JP2013125127A Pending JP2013199489A (ja) | 2006-06-06 | 2013-06-14 | 新規ピペラジン、医薬組成物、およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013125127A Pending JP2013199489A (ja) | 2006-06-06 | 2013-06-14 | 新規ピペラジン、医薬組成物、およびその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2044038B1 (enExample) |
| JP (2) | JP5363315B2 (enExample) |
| CA (1) | CA2659512C (enExample) |
| ES (1) | ES2498043T3 (enExample) |
| WO (1) | WO2007146066A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2659512C (en) * | 2006-06-06 | 2015-09-08 | Critical Therapeutics, Inc. | Novel piperazines, pharmaceutical compositions and methods of use thereof |
| US8304547B2 (en) | 2007-10-24 | 2012-11-06 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
| EP2336125B1 (en) | 2008-04-11 | 2013-01-09 | Janssen Pharmaceutica N.V. | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase |
| EP2351744B1 (en) | 2008-10-17 | 2015-01-07 | Shionogi & Co., Ltd. | Acetic acid amide derivative having inhibitory activity on vascular endothelial lipase |
| KR101051077B1 (ko) * | 2008-12-05 | 2011-07-21 | 한국화학연구원 | 2-피페라지노-4,5-이중치환-1,3-티아졸 유도체, 그의 제조방법 및 그를 유효성분으로 함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련질환 치료제 |
| US8399465B2 (en) | 2009-05-14 | 2013-03-19 | Janssen Pharmaceutica Nv | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase |
| AU2010291834A1 (en) * | 2009-09-04 | 2012-03-15 | Zalicus Pharmaceuticals Ltd. | Substituted heterocyclic derivatives for the treatment of pain and epilepsy |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| WO2011152442A1 (ja) * | 2010-06-03 | 2011-12-08 | 塩野義製薬株式会社 | 2－クロロ－6－フルオロベンゾオキサゾールの製造方法 |
| WO2012152741A1 (de) | 2011-05-10 | 2012-11-15 | Bayer Intellectual Property Gmbh | Bicyclische (thio)carbonylamidine |
| WO2012170867A1 (en) * | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
| EP2961403A4 (en) | 2013-03-01 | 2016-11-30 | Zalicus Pharmaceuticals Ltd | HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL |
| CN112500338A (zh) | 2013-03-15 | 2021-03-16 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| ES2714705T3 (es) * | 2013-07-10 | 2019-05-29 | Meiji Seika Pharma Co Ltd | Inhibidor de PDE4 novedoso |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| GB201401886D0 (en) | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
| FR3022784B1 (fr) * | 2014-06-26 | 2017-09-08 | Ecole Normale Superieure Lyon | Sondes moleculaires activables hydrosolubles, intermediaires pour leur synthese et procedes de detection associes |
| CN112920137A (zh) * | 2021-03-02 | 2021-06-08 | 南京波普生物医药研发有限公司 | 噻唑医药中间体合成工艺 |
| CN117003710A (zh) * | 2023-07-19 | 2023-11-07 | 镇江先锋植保科技有限公司 | 一种2-巯基-6-氯苯并恶唑的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2165176A1 (en) * | 1993-06-18 | 1995-01-05 | Samuel L. Graham | Inhibitors of farnesyl-protein transferase |
| IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
| EP0820452B1 (en) * | 1995-04-07 | 2003-06-04 | Schering Corporation | Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase |
| US5880128A (en) * | 1996-05-08 | 1999-03-09 | Schering Corporation | Carbonyl piperazinyl and piperidinyl compounds |
| US5929077A (en) * | 1996-11-08 | 1999-07-27 | Leftheris; Katerina | Thioproline-containing inhibitors of farnesyl protein transferase |
| US6372747B1 (en) * | 1998-12-18 | 2002-04-16 | Schering Corporation | Farnesyl protein transferase inhibitors |
| US6878700B1 (en) * | 1998-12-29 | 2005-04-12 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| WO2003016274A2 (en) * | 2001-08-21 | 2003-02-27 | Sepracor, Inc. | 2-substituted piperidines that are ligands for monoamine receptors and transporters |
| EP1592389B1 (en) * | 2003-02-14 | 2009-04-22 | Laboratoires Serono SA | Piperazine-2-carboxamide derivatives |
| CA2573223C (en) * | 2004-08-06 | 2013-05-21 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compound |
| CA2659512C (en) * | 2006-06-06 | 2015-09-08 | Critical Therapeutics, Inc. | Novel piperazines, pharmaceutical compositions and methods of use thereof |
-
2007
- 2007-06-06 CA CA2659512A patent/CA2659512C/en not_active Expired - Fee Related
- 2007-06-06 JP JP2009514375A patent/JP5363315B2/ja not_active Expired - Fee Related
- 2007-06-06 EP EP07809388.7A patent/EP2044038B1/en not_active Not-in-force
- 2007-06-06 ES ES07809388.7T patent/ES2498043T3/es active Active
- 2007-06-06 WO PCT/US2007/013425 patent/WO2007146066A2/en not_active Ceased
-
2013
- 2013-06-14 JP JP2013125127A patent/JP2013199489A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539848A5 (enExample) | ||
| JP2008515852A5 (enExample) | ||
| WO2008096870A1 (ja) | アザ架橋環化合物 | |
| JP2013537203A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2006525359A5 (enExample) | ||
| JP2009534407A5 (enExample) | ||
| JP2009534406A5 (enExample) | ||
| JP2009534405A5 (enExample) | ||
| EA201001127A1 (ru) | Производные пиридина | |
| JP2010535722A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| JP2009530283A5 (enExample) | ||
| JP2016505614A5 (enExample) | ||
| WO2007087427A3 (en) | Thiazole and thiadiazole compounds for inflammation and immune-related uses | |
| WO2008096231A8 (en) | Antiparasitic agents | |
| JP2009532417A5 (enExample) | ||
| WO2010145197A8 (en) | Novel 6-arylamino pyridone sulfonamides and 6-arylamino pyrazinone sulfonamdies as mek inhibitors | |
| JP2016507581A5 (enExample) | ||
| JP2011510068A5 (enExample) | ||
| JP2017508733A5 (enExample) | ||
| EA201001129A1 (ru) | Пиримидины в качестве ингибиторов киназы |